



Patent Docket P1129R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Avi J. Ashkenazi et al. Serial No.: 09/114,844 Filed: 14 July 1998 For: RTD RECEPTOR	Group Art Unit: 1646 Examiner: C. Kaufman
---	--

32/3
S.G.
6/10/03
RECEIVED
JUN 06 2003
TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Sir:

This paper is being filed concurrently with Applicants' Request for a Continued Prosecution Application (CPA). Entry of the amendment below is respectfully requested.

IN THE CLAIMS:

1. (Twice Amended) Isolated RTD polypeptide having at least 80% amino acid sequence identity with RTD polypeptide comprising amino acid residues 1 to 386 of Fig. 1A (SEQ ID NO:1), wherein said isolated RTD polypeptide inhibits Apo-2 ligand induced apoptosis in a mammalian cell or binds Apo-2 ligand.
2. (Once Amended) The RTD polypeptide of claim 1 wherein said RTD polypeptide has at least 90% amino acid sequence identity.
3. (Once Amended) The RTD polypeptide of claim 2 wherein said RTD polypeptide has at least 95% amino acid sequence identity.
4. (Once Amended) Isolated RTD polypeptide comprising amino acid residues 1 to 386 of Fig. 1A (SEQ ID NO:1).
5. (As filed) Isolated RTD polypeptide comprising amino acid residues 56 to 386 of Fig. 1A (SEQ ID NO:1).